Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Beyond the Genome 2012

Open Access Oral presentation

Interrogating of cancer genomes: towards more profile-based therapeutics

John David Carpten

  • Correspondence: John D Carpten

Author Affiliations

Division of Integrated Cancer Genomics, Translational Genomics Research Institute, Phoenix, AZ, USA

BMC Proceedings 2012, 6(Suppl 6):O16  doi:10.1186/1753-6561-6-S6-O16


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/6/S6/O16


Published:1 October 2012

© 2012 Carpten; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oral presentation

Although death rates due to common diseases such as heart disease, stroke and infectious diseases have declined over the last half-century, there has been only a small change in cancer mortality rates. The availability of the draft human genome sequence and a number of technological advances now provide us with the opportunity to explore the genomic landscape of cancer in an unprecedented way. Here, we will describe the application of multiple genomic technologies toward the interrogation of a number of cancer genomes, in order to discover molecular determinants of cancer that might be associated with clinical outcome and those that might be candidates for targeted therapy. It is our hope that these data would one day be translated into clinical practice to improve therapeutic decision-making for more knowledge-based clinical management.